Antiepileptics and bone health

Therapeutic Advances in Musculoskeletal Disease

Volumn 3, Issue 5, 2011, Pages 235-243

  Meier, Christian ^a   Kraenzlin, Marius E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

antiepileptics; epilepsy; fracture; metabolic bone disease; osteoporosis

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VITAMIN D;

BONE CHARACTERISTICS AND FUNCTIONS; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE STRENGTH; BONE TURNOVER; CAUSAL ATTRIBUTION; CHRONIC DRUG ADMINISTRATION; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; EPILEPSY; EPILEPTIC DISCHARGE; FRACTURE; HUMAN; HYPERPARATHYROIDISM; LOW DRUG DOSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SHORT STATURE; SIDE EFFECT; TREATMENT DURATION;

EID: 80855142290     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11410769     Document Type: Review

References (59)

1. Andress D.L. Ozuna J. Tirschwell D. Grande L. Johnson M. Jacobson A.F. et al (2002) Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 59: 781–786.
2. Babayigit A. Dirik E. Bober E. Cakmakci H. (2006) Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 35: 177–181.
3. Bartl R. (2007) [Antiepileptic drug-induced osteopathy. Subtypes, pathogenesis, prevention, early diagnosis and treatment]. Dtsch Med Wochenschr 132: 1475–1479.
4. Cansu A. Yesilkaya E. Serdaroglu A. Hirfanoglu T.L. Camurdan O. Gulbahar O. et al (2008) Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol 39: 266–271.
5. Coppola G. Fortunato D. Auricchio G. Mainolfi C. Operto F.F. Signoriello G. et al (2009) Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 50: 2140–2146.
6. Cummings S.R. Nevitt M.C. Browner W.S. Stone K. Fox K.M. Ensrud K.E. et al (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332: 767–773.
7. Drezner M.K. (2004) Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 5(Suppl. 2): S41–S47.
8. Ecevit C. Aydogan A. Kavakli T. Altinoz S. (2004) Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 31: 279–282.
9. El-Hajj Fuleihan G. Dib L. Yamout B. Sawaya R. Mikati M.A. (2008) Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 43: 149–155.
10. Ensrud K.E. Walczak T.S. Blackwell T. Ensrud E.R. Bowman P.J. Stone K.L. (2004) Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 62: 2051–2057.
11. Ensrud K.E. Walczak T.S. Blackwell T.L. Ensrud E.R. Barrett-Connor E. Orwoll E.S. (2008) Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 71: 723–730.
12. Farhat G. Yamout B. Mikati M.A. Demirjian S. Sawaya R. El-Hajj Fuleihan G. (2002) Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58: 1348–1353.
13. Fitzpatrick L.A. (2004) Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 5(Suppl. 2): S3–S15.
14. Guo C.Y. Ronen G.M. Atkinson S.A. (2001) Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42: 1141–1147.
15. Harden C.L. Herzog A.G. Nikolov B.G. Koppel B.S. Christos P.J. Fowler K. et al (2006) Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 47: 1447–1451.
16. Hoikka V. Alhava E.M. Karjalainen P. Keranen T. Savolainen K.E. Riekkinen P. et al (1984) Carbamazepine and bone mineral metabolism. Acta Neurol Scand 70: 77–80.
17. Howard G.M. Radloff M. Sevier T.L. (2004) Epilepsy and sports participation. Curr Sports Med Rep 3: 15–19.
18. Jette N. Lix L.M. Metge C.J. Prior H.J. McChesney J. Leslie W.D. (2011) Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 68: 107–112.
19. Jones G. Nguyen T. Sambrook P.N. Kelly P.J. Gilbert C. Eisman J.A. (1994) Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 4: 277–282.
20. Kanis J.A. Burlet N. Cooper C. Delmas P.D. Reginster J.Y. Borgstrom F. et al (2008 a) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19: 399–428.
21. Kanis J.A. Johnell O. Oden A. Johansson H. McCloskey E. (2008 b) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385–397.
22. Kanis J.A. Johnell O. Oden A. Sembo I. Redlund-Johnell I. Dawson A. et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11: 669–674.
23. Kanis J.A. McCloskey E.V. Johansson H. Strom O. Borgstrom F. Oden A. (2008 c) Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos Int 19: 1395–1408.
24. Kanis J.A. Oden A. Johansson H. Borgstrom F. Strom O. McCloskey E. (2009) FRAX and its applications to clinical practice. Bone 44: 734–743.
25. Kotsopoulos I.A. van Merode T. Kessels F.G. de Krom M.C. Knottnerus J.A. (2002) Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 43: 1402–1409.
26. Lamberg-Allardt C. Wilska M. Saraste K.L. Gronlund T. (1990) Vitamin D status of ambulatory and nonambulatory mentally retarded children with and without carbamazepine treatment. Ann Nutr Metab 34: 216–220.
27. Lippuner K. Johansson H. Kanis J.A. Rizzoli R. (2009) Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20: 1131–1140.
28. Mattson R.H. Gidal B.E. (2004) Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 5(Suppl. 2): S36–S40.
29. Meier C. Seibel M.J. Kraenzlin M.E. (2008) Biochemical markers of bone turnover: Clinical aspects. In: Ed. Adler R.A. (ed.) Osteoporosis: Pathophysiology and Clinical Management 2nd ed. Humana Press: Totowa, NJ.
30. Meier C. Seibel M.J. Kraenzlin M.E. (2009) Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res 24: 386–388.
31. Mintzer S. (2010) Metabolic consequences of antiepileptic drugs. Curr Opin Neurol 23: 164–169.
32. Mintzer S. Boppana P. Toguri J. DeSantis A. (2006) Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47: 510–515.
33. Nakken K.O. Rytter E.M. Brockmeier F. (2010) [Benzodiazepines in the treatment of epilepsy]. Tidsskr Nor Laegeforen 130: 842–844.
34. Nakken K.O. Tauboll E. (2010) Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf 9: 561–571.
35. Nissen-Meyer L.S. Svalheim S. Tauboll E. Reppe S. Lekva T. Solberg L.B. et al (2007) Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 48: 1850–1860.
36. Pack A. (2008) Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 17: 181–186.
37. Pack A.M. Morrell M.J. (2004) Epilepsy and bone health in adults. Epilepsy Behav 5(Suppl. 2): S24–S29.
38. Pack A.M. Morrell M.J. Marcus R. Holloway L. Flaster E. Done S. et al (2005) Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 57: 252–257.
39. Pack A.M. Morrell M.J. Randall A. McMahon D.J. Shane E. (2008) Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 70: 1586–1593.
40. Persson H.B. Alberts K.A. Farahmand B.Y. Tomson T. (2002) Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 43: 768–772.
41. Petty S.J. O'Brien T.J. Wark J.D. (2007) Anti-epileptic medication and bone health. Osteoporos Int 18: 129–142.
42. Sander J.W. (2003) The epidemiology of epilepsy revisited. Curr Opin Neurol 16: 165–170.
43. Sato Y. Kondo I. Ishida S. Motooka H. Takayama K. Tomita Y. et al (2001) Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57: 445–449.
44. Seibel M.J. (2000) Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 11(Suppl. 6): S18–S29.
45. Sheth R.D. Binkley N. Hermann B.P. (2008) Progressive bone deficit in epilepsy. Neurology 70: 170–176.
46. Sheth R.D. Gidal B.E. Hermann B.P. (2006) Pathological fractures in epilepsy. Epilepsy Behav 9: 601–605.
47. Sheth R.D. Hermann B.P. (2007) Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol 37: 250–254.
48. Sheth R.D. Wesolowski C.A. Jacob J.C. Penney S. Hobbs G.R. Riggs J.E. et al (1995) Effect of carbamazepine and valproate on bone mineral density. J Pediatr 127: 256–262.
49. Souverein P.C. Webb D.J. Petri H. Weil J. van Staa T.P. Egberts T. (2005) Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 46: 304–310.
50. Souverein P.C. Webb D.J. Weil J.G. van Staa T.P. Egberts A.C. (2006) Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 66: 1318–1324.
51. Stephen L.J. McLellan A.R. Harrison J.H. Shapiro D. Dominiczak M.H. Sills G.J. et al (1999) Bone density and antiepileptic drugs: a case-controlled study. Seizure 8: 339–342.
52. Tsiropoulos I. Andersen M. Nymark T. Lauritsen J. Gaist D. Hallas J. (2008) Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia 49: 2092–2099.
53. Valimaki M.J. Tiihonen M. Laitinen K. Tahtela R. Karkkainen M. Lamberg-Allardt C. et al (1994) Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 9: 631–637.
54. Valmadrid C. Voorhees C. Litt B. Schneyer C.R. (2001) Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 58: 1369–1374.
55. Verrotti A. Coppola G. Parisi P. Mohn A. Chiarelli F. (2010) Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 112: 1–10.
56. Verrotti A. Greco R. Latini G. Morgese G. Chiarelli F. (2002) Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43: 1488–1492.
57. Vestergaard P. (2005) Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand 112: 277–286.
58. Vestergaard P. Rejnmark L. Mosekilde L. (2004) Fracture risk associated with use of antiepileptic drugs. Epilepsia 45: 1330–1337.
59. Weinstein R.S. Bryce G.F. Sappington L.J. King D.W. Gallagher B.B. (1984) Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 58: 1003–1009.